Drug evaluation: Reolysin - Wild-type reovirus as a cancer therapeutic

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 3, 2006, Pages 249-260

  Stoeckel, Jessica ^a   Hay, John G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CG 7060; CG 8840; CISPLATIN; CREATINE KINASE MB; CYCLOSPORIN A; DOXORUBICIN; FLUOROURACIL; G 207; GEMCITABINE; H 101; HSV 1716; NV 1020; ONCOLYTIC VIRUS; ONYX 015; PACLITAXEL; RAS PROTEIN; REOLYSIN; REOSYN; TROPONIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BILE DUCT ATRESIA; BLADDER CANCER; BREAST CANCER; CANCER; CHILDHOOD CANCER; CLINICAL TRIAL; COLON CANCER; CREATINE KINASE BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG FECES LEVEL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RELEASE; DRUG SCREENING; DRUG URINE LEVEL; ENZYME DEFECT; FATIGUE; FLU LIKE SYNDROME; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LYMPHOCYTOPENIA; MEDULLOBLASTOMA; MELANOMA; MYALGIA; NEUTROPENIA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN DEFECT; RECURRENT CANCER; REOVIRUS; RHINORRHEA; RIGOR; SARCOMA; SWEAT GLAND DISEASE; VACCINIA VIRUS; VIRUS INFECTION; WILD TYPE;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATENTS; PATENTS AS TOPIC; REOVIRIDAE; STRUCTURE-ACTIVITY RELATIONSHIP;

REOVIRUS SP.;

EID: 33744908612     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. 24 Ras oncogenes in human cancer: A review. Bos JL CANCER RES 1989 49 17 4682-4689
2. 52 Oncolytics Biotech Inc announces initiation of REOLYSIN clinical study. Oncolytics Biotech Inc PRESS RELEASE 2000 June 06
3. 06 A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randiev B, Gillenwater AM, Bruso P, Kaye SB NAT MED 2000 6 8 879-885
4. 91 A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. Mohr I, Gluzman Y EMBO J 1996 15 17 4759-4766
5. 24 Efficacy and safety evaluation of human reovirus type 3 in a immunocompetent racine glioma model. Yang WQ, Wilcox EM, Shi Z, Dyck RH, Muzik H, Rewcastle BN, Brasher P, Lee P, Forsyth PA PROC AM ASSOC CANCER RES 2001 42 Abs 2436
6. 26 Reovirus therapy of metastatic cancer models in immune-competent mice. Hirasawa K, Yoon C-S, Nishikawa SG, Waisman DM, Lee PWK PROC AM ASSOC CANCER RES 2001 42 Abs 2437
7. 55 Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tomatore C, Tufaro F, Martuza RL GENE THER 2000 7 10 867-874
8. 59 Reovirus as an oncolytic agent against experimental human malignant gliomas. Wilcox ME, Yang W, Sanger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA J NATL CANCER INST 2001 93 12 903-912
9. 72 A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR Carducci MA, Nelson WG, Simons JW CANCER RES 2001 61 20 7464-7472
10. 76 A phase I clinical trial evaluating intralesional REOLYSIN (Reovirus) in histologically confirmed malignancies. Morris DG, Forsyth PA, Paterson AH, Fonseca K, Difrancesco LM, Thompson BG, Coffey MC PROC AM SOC CLIN ONCOL 2002 21 1 Abs 92
11. 86 Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, J CLIN ONCOL 2002 20 9 2251-2266
12. 81 Oncolytics commences phase I/II brain cancer trial. Oncolytics Biotech Inc PRESS RELE4SE 2002 July 03
13. 13 Reolysin safe, phase I malignant glioma study says. Oncolytics Biotech Inc PRESS RELEASE 2002 December 23
14. 32 Oncolytics' Reolysin shows efficacy in T2 prostate cancer trial. La Jolla Pharmaceutical Co PRESS RELEASE 2003 April 01
15. 93 Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC Jr, Mulholland SG, Lattime EC J UROL 2001 166 4 1291-1295
16. 05 Cell & Gone Therapies - SMi Conference, London, UK. Aird J IDDB MEETING REPORT 2003 September 24-25
17. 27 Oncolytics receives approval for systemic Reolysin trial. Oncolytics Biotech Inc PRESS RELEASE 2004 March 01
18. 48 Oncolytics starts dosing in phase I Reolysin cancer trial. Oncolytics Biotech Inc PRESS RELEASE 2004 May 26
19. 47 The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT116. Wadler S, Yu B, Lane M, Klampfer L, Sasazuki T, Shirasawa S, Coffey M EUR J CANCER SUPPL 2004 2 8 Abs 452
20. 88 Oncolytics' phase I trial of Reolysin with chemotherapy gets go-ahead. Oncolytics Biotech Inc PRESS RELEASE 2005 February 18
21. 50 Oncolytics to start Reolysin phase I advanced cancer trial. Oncolytics Biotech Inc PRESS RELEASE 2005 April 07
22. 85 Potential role for reovirus in the treatment of melanoma: Targeted killing and immune stimulation. Errington F, Coffey MC, Hatfield P, Harrington K, Melcher AA PROC AM ASSOC CANCER RES 2005 96 Abs 6040
23. 98 Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M GENE THER 2000 7 10 859-866
24. 96 Making intracellular peptide therapeutics come true for the treatment of major debilitating diseases. Xigen SA COMPANY WORLD WIDE WEB SITE 2005 June 30
25. 60 The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, Harland J, Mabbs R, GENE THER 2002 9 6 398-406
26. 62 HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety date and long-term survival. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, Hadley D, Patterson J, Brown SM, Rampling R GENE THER 2004 11 22 1648-1658
27. 92 Oncolytics Biotech Inc begins patient enrolment in US systemic delivery clinical trial. Oncolytics Biotech Inc PRESS RELEASE 2005 September 28
28. 84 A phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies. Vidal L, Pandha H, Harrington K, Fong P, Shaw H, Barrett M, Leader D, Mile C, Twigger K, Coffey M, Thompson B, Kaye S, De-Bono J CLIN CANCER RES 2005 11 23 suppl Abs C31
29. 00 Sunway's oncolytic adenovirus approved in China. Shanghai Sunway Biotech Co Ltd PRESS RELEASE 2005 November 17
30. 52 Reovirus therapy of tumors with activated Ras pathway. Coffey MC, Strong JE, Forsyth PA, Lee PW SCIENCE 1998 282 5392 1332-1334
31. 54 Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW PROC NTL ACAD SCI USA 2004 101 30 11099-11104
32. 56 Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Yang WQ, Senger D, Muzik H, Shi ZQ, Johnson D, Brasher PM, Rewcastle NB, Hamilton M, Rutka J, Wolff J, Wetmore C, Curran T, Lee PW, Forsyth PA CANCER RES 2003 63 12 3162-3172
33. 58 Systemic reovirus therapy of metastatic cancer in immune-competent mice. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW CANCER RES 2003 63 2 348-353
34. 60 Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts. Thirukkumaran CM, Luider JM, Stewart DA, Alain T, Russell JA, Auer IA, Forsyth P, Morris DG BONE MARROW TRANSPL 2005 35 11 1055-1064
35. 62 Oncolytic reovirus against ovarian and colon cancer. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW CANCER RES 2002 62 6 1696-1701
36. 65 Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Thirukkumaran CM, Luider JM, Stewart DA, Chang T, Lupichuk SM, Nodwell MJ, Russell JA, Auer IA, Morris DG BLOOD 2003 102 1 377-387
37. 67 Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: Racine and nonhuman primates. Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ, Dyck R, Coffey M, Thompson B, Hamilton M, Nishikawa SG, Brasher PM, Fonseca K, George D, Rewcastle NB, Johnston RN, Stewart D, Lee PW, Sanger DL, Forsyth PA CLIN CANCER RES 2004 10 24 8561-8576
38. 69 Requirement for Nuclear b-catenin in HTLV-1 Tax-induced transactivation: Identification of a new molecular target for the treatment of adult T-cell leukemia. Lee MJ, Chung EJ, Lee S, Brady JN, Trepel JB CLIN CANCER RES 2005 11 23 suppl Abs C172
39. 70 Reovirus oncolysis of human breast cancer. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW HUM GENE THER 2002 13 5 641-652
40. 73 Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic. Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ CANCER BIOL THER 2004 3 8 734-738
41. 31 Reovirus enhances radiation cytotoxicity in vitro and in vivo. Vidal L, Twigger K, White C, Coffey M, Thompson B, De-Bono J, Pandha HS, Melcher A, Kaye S, Harrington KJ CLIN CANCER RES 2005 11 23 Suppl Abs A170
42. 92 Genetics of Reovirus. Fields BN CURR TOP MICROBIOL IMMUNOL 1981 91 1-24
43. 94 Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Sabin AB SCIENCE 1959 130 1387-1389
44. 96 Biliary atresia: An update on our understanding of the disorder. Narkewicz MR CURR OPIN PEDIATR 2001 13 5 435-440
45. 04 Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts. Tyler KL, Sokol RJ, Oberhaus SM, Le M, Kamer FM, Narkewicz MR, Tyson RW, Murphy JR, Low R, Brown WR HEPATOLOGY 1998 27 6 1475-1482
46. 07 Lack of conformation of the association of reovirus 3 and biliary atresia: Methodological differences. Brown WR HEPATOLOGY 1990 12 5 1254-1255
47. 09 Biliary atresia and reovirus type 3 infection. Dussaix E, Hadchouel M, Tardieu M, Alagille D N ENGL J MED 1984 310 10 658
48. 14 Comparative studies of biliary atresia in the human newborn and reovirus-induced cholanglitis in weanling mice. Bangaru B, Morecki R, Glaser JH, Gartner LM, Horwitz MS LAB INVEST 1980 43 5 456-462
49. 21 Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K, Kelly JK J HEPATOL 1987 5 1 8-13
50. 25 Reovirus 3 and neonatal biliary disease: discussion of divergent results. Morecki R, Glaser J HEPATOLOGY 1989 10 4 515-517
51. 27 A study of human reovirus IgG and IgA antibodies by ELISA and western blot. Selb B, Weber B J VIROL METHODS 1994 47 1-2 15-25
52. 33 Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE Jr, Dermody TS J INFECT DIS 2005 191 8 1221-1224
53. 48 Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Mastrangelo W, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC CANCER GENE THER 1999 6 5 409-422
54. 60 Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T MOL THER 2006 13 1 221-228
55. 49 Phase I trial of intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients with advanced malignancies. Vidal L, Twigger K, White CL, Ahmed M, Pandha HS, Nutting CM, De Bono JS, Kaye SB, Melchor A, Harrington KJ PROC AM ASSOC CANCER RES 2006 97 Abs 3998
56. 51 Reolysin, an unmodified Reovirus, has significant anti-tumor activity in childhood sarcomas. Zhang WE, Kolb EA PROC AM ASSOC CANCER RES 2006 97 Abs 4331
57. 72 Reovirus infections in human volunteers. Rosen L, Evans HE, Spickard A AM J HYG 1963 77 29-37
58. 73 Phase III randomized clinical trial of intratumorall injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng X AI ZHENG CHINESE 2004 23 12 1666-1670
59. 99 NeoRx completes $65 million stock placement. Neorx Corp PRESS RELEASE 2006 April 27
60. 29 Clinical trial information: Reolysin. Oncolytics Biotech Inc COMPANY WORLD WIDE WEB SITE 2006 April 27 http://www.oncolyticsbibtech. com
61. 54 Process development of a scaleable purification protocol for the production of Reolysin, an oncolytic, reovirus-based therapeutic. Sibylle UH, Peder B, Lemmens R, Coffey M, Moore MP ANN MEET AM SOC GENE THER 2005 Abs 174
62. 86 Mutant KRAS promotes apoptosis of Reovirus-infected colorectal tumor cells without affecting virus replication. Smakman N, Van den Wollenberg D, Hoeben R, Rinkes IB, Kranenburg O PROC AM ASSOC CANCER RES 2006 97 Abs 4217
63. 98 Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A, Kitano S CLIN CANCER RES 2003 9 3 1218-1223
64. 00 A novel intravesical therapy for superficial bladder cancer in an orthotopic model: Oncolytic reovirus therapy. Hanel EG, Xiao Z, Wong KK, Lee PW, Britten RA, Moore RB J UROL 2004 172 5 Pt 1 2018-2022
65. 72 Immunosuppression promotes reovirus therapy of colorectal liver metastases. Smakman N, van der Bilt JD, van den Wollenberg DJ, Hoeben RC, Borel Rinkes IH, Kranenburg O CANCER GENE THER 2006 Epub ahead of print
66. 84 Reovirus salvage of positive resection margin: A novel treatment adjunct. Mechor B, Seikaly H, Wong K, Chau J, Uwiera R, Harris JR. J OTOLARYNGOL 2006 35 2 97-101
67. 85 Reovirus salvage of squamous cell cancer-contaminated wounds. Brookes JT, Seikaly H, Lim T, Wong KK, Harris JR, Moore RB J OTOLARYNGOL 2005 34 1 32-37
68. 92 Reovirus has in vivo oncolytic effect on cells cured of reovirus in vitro. Alain T, Kim M, Johnston RN, Urbanski SJ, Kossakowska AE, Forsyth PA, Lee PWK PROC AM ASSOC CANCER RES 2005 96 Abs 360
69. 93 Acquired resistance to reoviral oncolysis. Kim M, Egan C, Lee PWK, Forsyth PAJ, Johnston RN PROC AM ASSOC CANCER RES 2005 96 Abs 3381
70. 98 Gene expression profiling of reovirus oncolysis in breast cancer. Thirukkumaran CM, Thirukkumaran P, Morris D PROC AM ASSOC CANCER RES 2005 96 Abs 24
71. 88 Increasing complexity of Ras signaling. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ ONCOGENE 1998 17 11 1395-1413
72. 12 Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Yang WQ, Senger DL, Lun XQ, Muzik H, Shi ZQ, Dyck RH, Norman K, Brasher PM, Rewcastle NB, George D, Stewart D, Lee PW, Forsyth PA GENE THER 2004 11 21 1579-1589